Skip to main content
. 2005 Aug;43(8):3642–3649. doi: 10.1128/JCM.43.8.3642-3649.2005

TABLE 1.

Patients and strain characteristics

Patientm Isolate Onseta (days) Sexb Age (yr) Infection statusc Underlying diseased Treatmente MICf (μg/ml) of VA/TEC PFGEn PCRg
vanA IS16 IS16-vanY
I 8 20 M 85 UTI Prostatic cancer None 256/16 A + + +
II 13 15 F Peritonitis Lymphoma LZD, SXT 12/4 A + + +
III 11 20 F 64 Bacteremia Transplantation + ESRD None 24/6 A + + +
IV 9 7 F 77 UTI Diabetes + ARF None 24/6 A + + +
10h 21 F 77 C Diabetes + ARF - 16/8 A + + +
V 5 21 M 80 Peritonitis ESRD LZD, SXT 256/8 A + + +
VI 4 22 F 67 UTI Diabetes + ARF None 24/8 A + + +
VII 1 4 F 63 UTI Transplantation + ESRD None 12/6 A + + +
VIII 3 15 F 68 C ESRD - 24/6 A + + +
IX 14 10 F 75 C Myeloma - 24/8 A + + +
X 2 11 F 48 C Transplantation - 12/6 A + + +
XI 12 8 F 45 C Transplantation - 256/48 A + + −
XII 20i 23 F 54 C Transplantation - 256/32 B + + −
21 23 F 48 C Transplantation - 32/8 A + + +
XIII 17 10 59 C Transplantation + polycystic kidney disease - 24/8 A + + +
XIV 15 5 M 55 C Nephroangiosclerosis - 256/16 A + + +
XV 16 24 F 39 C Transplantation - 96/16 A + + +
XVI 18 15 F 44 C Immunoglobulin A nephropathy - 32/6 A + + +
XVII 19 21 F 69 C Amyloid kidney - 24/12 A + + +
XVIII 23 4 M 75 C Myeloma - 16/6 A + + +
XIX 22 4 M 65 C Liver cirrhosis - 32/16 A + + +
XX 24 23 F 45 C Transplantation - 32/12 A + + +
XXI 28 2 M 69 C Transplantation + diabetes - 256/6 A1 + + +
XXII 25 14 F 30 C ESRD - 16/6 A + + +
XXIII 27 5 M 77 C ESRD - 256/48 A + + −
XXIV 29 24 F 62 C ARF - 32/12 A + + +
C1j 6 256/48 C + − −
C2k 7 48/0.5 D − − −
C3l 26 0.25/0.25 E - - -
a

Onset corresponds to the number of days of hospitalization prior to VRE isolation.

b

M, male; F, female.

c

UTI, urinary tract infection; C, colonization.

d

Reason for hospital admission. ARF, acute renal failure; ESRD, end-stage renal disease.

e

Treatment is only indicated for VRE infections. LZD, linezolid; SXT, trimethoprim-sulfamethoxazole; None, no antibiotic. -, Not relevant (since colonized patients were not treated for VRE).

f

MICs of vancomycin (VA) and teicoplanin (TEC).

g

PCR results for vanA gene, IS16, and IS16 inserted within the vanY gene.

h

This isolate was resistant to trimethoprim-sulfamethoxazole.

i

This isolate was resistant at low levels to gentamicin and to trimethoprim-sulfamethoxazole.

j

CI, BM4147 VanA prototype.

k

C2, E. faecium V883 VanB prototype.

l

C3, E. faecium Gil (vancomycin susceptible).

m

The numbering in Roman numerals corresponds to the patients listed in chronological order. For two patients, two strains were identified with a different antibiotic susceptibility profile. The strain numbering in Arabic numerals corresponds to the order in which the strains were identified as vanA genotype.

n

Pulsotypes are according to Tenover et al. (34).